research Regarding prostate-specific antigen: let's not shoot the messenger
The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
Search
for
Sort by
Research
450-480 / 1000+ results research SHPro ® (mixture of Angelica gigas and Astragalus membranaceus ) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial
SHPro® improved urinary symptoms and erectile function in men and is safe.
research Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism
The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
research In vitro and In vivo Effects of 17β-N-(4-phenylcarbamoyl) androst-4-en-3- one Derivatives as 5a-reductase Inhibitors on Androgen-dependent Glands
Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
research Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
5α-reductase inhibitors like finasteride and dutasteride can help treat skin disorders stimulated by androgens, such as hair loss and acne.
research Finasteride for recurrent priapism in children and adolescents: A report on 5 cases
Finasteride may help treat recurrent priapism in children, but more research is needed.
research VIBRATIONAL SPECTROSCOPIC INVESTIGATION AND MOLECULAR STRUCTURE OF A 5α-REDUCTASE INHIBITOR: FINASTERIDE
The PW91 method is best for calculating the basic physical and chemical properties of Finasteride, a drug used for prostate issues and hair loss.
research CAN PATIENTS WITH LUTS AND BPH DISCERN CHANGES IN PEAK URINARY FLOW RATE AND DO SUCH CHANGES CONTRIBUTE TO OVERALL SATISFACTION WITH TREATMENT?
Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
research Finasteride for prostatic disease: an updated and comprehensive review
Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
research Molecular interactions of progesterone derivatives with 5α-reductase types 1 and 2 and androgen receptors
Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
research 5α-Reductase inhibitors in androgenetic alopecia
Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
research Enzyme Inhibitory Activities of Marine Sponges Against Cholinesterase and 5α-Reductase
Marine sponges from Tabuhan Island can inhibit enzymes linked to Alzheimer's and hair loss.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.
research Therapeutic potential of isoproterenol in androgenetic alopecia: activation of hair follicle stem cells via the PI3K/AKT/β-Catenin signaling pathway
Isoproterenol may help treat hair loss by activating hair follicle stem cells.
research Effectiveness and safety of finasteride in male chronic pelvic pain syndrome
Finasteride effectively reduces symptoms of male chronic pelvic pain syndrome with few side effects.
research Administration of dutasteride in animal models of retinitis pigmentosa
Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
research Finasteride Attenuates Pathological Gambling in Patients With Parkinson Disease
Finasteride reduces gambling symptoms in Parkinson's patients.
research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
research Structural basis for the catalysis and inhibition of human steroid 5α‐reductase 2
The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.
research A high-performance liquid chromatography–tandem mass spectrometry assay of the androgenic neurosteroid 3α-androstanediol (5α-androstane-3α,17β-diol) in plasma
Testosterone increases 3α-androstanediol levels, which can be blocked by finasteride.
research Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome
research Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
research 5‐Alpha reductase inhibitor related litigation: A legal database review
Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
research The use of 5 alpha-reductase in the era of minimally invasive surgical therapies (MISTs): Is it still valuable?
research Inhibitory Effect of Extract of Urtical Mairei Levl on 5α-Reductase Activity
The root extract of Untica mairei Levl may help treat benign prostatic hyperplasia.
research 5α-Reductases In Human Physiology: an Unfolding Story
We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.
research New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
research Solubilization and Solid‐State Characterization of a Poorly Soluble 5‐α Reductase Inhibitor
GI197111X is best dissolved in Capmul MCM for trials.